Andy Barrett, PhD

Andy Barrett, PhD has a strong background in scientific and medical affairs, with experience in various leadership roles. Andy is currently serving as the Chief Scientific Officer at Cessation Therapeutics, LLC since September 2022. Prior to this, they worked at KemPharm, Inc. where they held the position of Vice President, Scientific Affairs from June 2017 to September 2022, and Senior Director, Scientific Affairs from February 2016 to June 2017. Before KemPharm, they were a Senior Director of Medical Affairs at Chimerix, Inc. from May 2015 to February 2016. Additionally, they worked at Salix Pharmaceuticals as a Director, Medical and Scientific Communications, Medical Affairs from August 2014 to April 2015, and as an Associate Director, Medical and Scientific Communications, Medical Affairs from July 2012 to July 2014. Prior to Salix Pharmaceuticals, they served as the Medical Director at Synchrony Healthcare from May 2011 to August 2012. Andy also has experiences at Cephalon, Inc., where they held multiple positions including Director, Therapeutics, Medical Science Liaisons from January 2011 to May 2011, Therapeutic Associate Director, Medical Science Liaisons from May 2008 to December 2010, Senior Medical Science Liaison from January 2007 to May 2008, and Medical Science Liaison from October 2005 to December 2006. Andy Barrett, PhD has a strong and diverse work experience in scientific and medical affairs, with a focus on leadership and communications.

Andy Barrett, PhD, completed their education in chronological order as follows:

From 1998 to 2003, they pursued a Ph.D. in Biological Psychology at the University of North Carolina at Chapel Hill.

Subsequently, they undertook a Postdoctoral Fellowship in Neuroscience and Drug Abuse from 2003 to 2005 at Harvard Medical School.